Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics

International Clinical Psychopharmacology

Volumn 25, Issue 4, 2010, Pages 241-245

  González Pinto, Ana ^a   Mosquera, Fernando ^a   Palomino, Aitor ^a   Alberich, Susana ^a   Gutiérrez, Arantza ^a   Haidar, Karim ^a   Vega, Patricia ^a   Barbeito, Sara ^a   Ortiz, Agurtzane ^a   Matute, Carlos ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Atypical antipsychotic; BDNF; First psychotic episode; Olanzapine

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; OLANZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MANIA; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SOCIOECONOMICS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 77953701074     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328338bc5a     Document Type: Article

References (42)

1. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. 4th edition (DSM-IV). Washington, DC: American Psychiatric Association.
2. Angelucci F, Mathé AA, Aloe L (2004). Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog Brain Res 146:151-165.
3. Angelucci F, Brenè S, Mathé AA (2005). BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 10:345-352.
4. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM (2003). Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 71:127-131.
5. Bramham CR, Messaoudi E (2005). BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 76:99-125.
6. Brown RW, Perna MK, Maple AM, Wilson TD, Miller BE (2008). Adulthood olanzapine treatment fails to alleviate decreases of ChAT and BDNF RNA expression in rats quinpirole-primed as neonates. Brain Res 1200:66-77.
7. Buckley PF, Mahadik S, Pillai A, Terry A Jr (2007a). Neurotrophins and schizophrenia. Schizophr Res 94:1-11.
8. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S (2007b). Brain derived neurotrophic factor in first-episode psychosis. Schizophr Res 91:1-5.
9. De Oliveira GS, Ceresér KM, Fernandes BS, Kauer-Sant'Anna M, Fries GR, Stertz L, et al. (2009). Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res 43:1171-1174.
10. Duman RS (2002). Synaptic plasticity and mood disorders. Mol Psychiatry 7 (Suppl 1):S29-S34.
11. Durany N, Thome J (2004). Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry 19:326-337.
12. Durany N, Michel T, Zöchling R, Boissl KW, Cruz-Sánchez FF, Riederer P, et al. (2001). Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 52:79-86.
13. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S (2001). Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacol 158:100-106.
14. Fumagalli F, Molteni R, Roceri M, Bedogni F, Santero R, Fossati C, et al. (2003). Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity. J Neurosci Res 72: 622-628.
15. Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F (2007). Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 420:45-48.
16. González-Pinto A, Tohen M, Lalaguna B, Pérez-Heredia JL, Fernandez-Corres B, Gutierrez M, et al. (2002). Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine. J Clin Psychopharmacol 22:450-454.
17. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, et al. (2006). Olanzapine and haloperidol in first episode psychosis: two-year data. Schizo-phr Res 86:234-243.
18. Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR (2007). Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 41:31-35.
19. Hammonds MD, Shim SS (2009). Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 105:113-119.
20. Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, et al. (2007). Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 22:21-27.
21. Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S (2006). Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 26:453-461.
22. Luo C, Xu H, Li XM (2004). Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine. Brain Res 1025:194-202.
23. Matute C, Melone M, Vallejo-Illarramendi A, Conti F (2005). Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 49:451-455.
24. Palomino A, Vallejo-Illarramendi A, González-Pinto A, Aldama A, González-Gómez C, Mosquera F, et al. (2006). Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 86:321-322.
25. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ (1998). Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacol 37:1553-1561.
26. Parikh V, Khan MM, Mahadik SP (2004). Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett 356:135-139.
27. Peralta V, Cuesta M (1994). Validation of positive and negative symptom scale (PANSS) in a sample of Spanish schizophrenic patients. Actas Luso Esp Neurol Psiquiatr 22:171-177.
28. Piccinni A, Marazziti D, Del Debbio A, Bianchi C, Roncaglia I, Mannari C, et al. (2008). Diurnal variation of plasma brain-derived neurotrophic factor (BDNF) in humans: an analysis of sex differences. Chronobiol Int 25:819-826.
29. Pillai A (2008). Decreased expression of Sprouty2 in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder: a correlation with BDNF expression. PLoS ONE 3:e1784.
30. Pillai A, Terry AV Jr, Mahadik SP (2006). Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat stria-tum and hippocampus. Schizophr Res 82:95-106.
31. Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A, Vasilopoulos D, et al. (2008). Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 10:1-5.
32. Shimizu E, Hashimoto K, Watanabe H, Komatsu N, Okamura N, Koike K, et al. (2003). Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 351: 111-114.
33. Shoval G, Weizman A (2005). The possible role of neurotrophins in the patho-genesis and therapy of schizophrenia. Eur Neuropsychopharmacol 15: 319-329.
34. Tamayo JM, Mazzotti G, Tohen M, Gattaz WF, Zapata R, Castillo JJ, et al. (2007). Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and halo-peridol. J Clin Psychopharmacol 27:126-134.
35. Tan QR, Wang XZ, Wang CY, Liu XJ, Chen YC, Wang HH, et al. (2007). Differential effects of classical and atypical antipsychotic drugs on rotenone-induced neurotoxicity in PC12 cells. Eur Neuropsychopharmacol 17:768-773.
36. Taylor S, Srinivasan B, Wordinger RJ, Roque RS (2003). Glutamate stimulates neurotrophin expression in cultured Müller cells. Brain Res Mol Brain Res 111:189-197.
37. Thacker SK, Perna MK, Ward JJ, Schaefer TL, Williams MT, Kostrzewa RM, et al. (2006). The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. Eur J Neurosci 24:2075-2083.
38. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. (2003). A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 60:1218-1226.
39. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, et al. (2002). Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 110:249-257.
40. Vallejo-Illarramendi A, Torres-Ramos M, Melone M, Conti F, Matute C (2005). Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures. Glia 50:276-279.
41. Valvassori SS, Stertz L, Andreazza AC, Rosa MI, Kapczinski F, Streck EL, et al. (2008). Lack of effect of antipsychotics on BDNF and NGF levels in hippocampus of Wistar rats. Metab Brain Dis 23:213-219.
42. Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J (2008). Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 2:1-6.